All In Biotech

Drug Trial Radar · NCT07091929

A Research Study to Evaluate the Safety and Preliminary Efficacy of SGC001 in Patients With Myocardial Infarction

A Randomized, Double-Blind, Placebo-Controlled, Single-Dose Escalation Phase Ib Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile, Immunogenicity, and Preliminary Efficacy of SGC001 in Chinese Patients Scheduled to Undergo Percutaneous Coronary Intervention for Anterior ST-segment Elevation Myocardial Infarction

Last checked: Nov 19, 2026Latest source record: Jan 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

38

Actual

Start

Jan 20, 2025

Primary completion

Jul 18, 2025

Study completion Jul 18, 2025

Sponsor

Sponsor type
Industry
First posted
Jul 29, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The research study is being done to see if SGC001 can be used to treat people scheduled to undergo percutaneous coronary intervention for Anterior ST-segment Elevation Myocardial Infarction. SGC001 might reduce the infarct size and inhibited inflammation, thereby preventing the incidence of major adverse cardiovascular events(MACE) events. Participants will either get SGC001 (active medicine) or placebo (a dummy medicine which has no effect on the body). Which treatment participants get is decided by chance. The chance of getting SGC001 or placebo is the same. The participant was administered intravenously once. SGC001 is not yet approved in any country or region in the world. It is a new medicine that doctors cannot prescribe.

Conditions

  • Anterior Myocardial Infarction

Interventions

  • SGC001Drug

    The single dose should be administered within 6 hours after the onset of acute myocardial infarction symptoms, with earlier administration preferred. The intravenous injection should be administered over 10 minutes.

  • PlaceboDrug

    The single dose should be administered within 6 hours after the onset of acute myocardial infarction symptoms, with earlier administration preferred. The intravenous injection should be administered over 10 minutes.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse events (AE), Serious adverse events (SAE)Time frame: From randomisation to end-of-study (up to 30 days)
  2. Recommended Phase 2 dose (RP2D)Time frame: From randomisation to end-of-study (up to 30 days)

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Anzhen Hospital Capital Medical University

    Beijing, Beijing Municipality, China

  • The 2nd Affiliated Hospital of Harbin Medical University

    Harbin, Heilongjiang, China

  • Linfen Central Hospital

    Linfen, Shanxi, China

  • Teda International Cardiovascular Hospital

    Tianjin, Tianjin Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.